Cawkwell Gail 4
4 · Aclaris Therapeutics, Inc. · Filed Jul 5, 2023
Insider Transaction Report
Form 4
Cawkwell Gail
Chief Medical Officer
Transactions
- Tax Payment
Common Stock
2023-07-01$10.37/sh−5,407$56,071→ 9,593 total - Exercise/Conversion
Common Stock
2023-07-01+15,000→ 15,000 total - Exercise/Conversion
Restricted Stock Units
2023-07-01−15,000→ 45,000 total→ Common Stock (15,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- [F3]The shares underlying these restricted stock units vest in four equal annual installments beginning on July 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.